Posts

Posted on

Everest Medicines Announces First Patient Dosed in Phase 3 Registration Asian Study of TrodelvyTM (sacituzumab govitecan) for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

SHANGHAI, China, Dec. 09, 2020 (GLOBE NEWSWIRE) — Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, today announced that the first patient has been dosed in the Phase 3 registration Asian study EVER-132-002 evaluating TrodelvyTM (sacituzumab govitecan) versus treatment of physician’s choice (TPC) in subjects with hormonal receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer (mBC).

EVER-132-002 is a Phase 3 Asian study designed to assess and compare the efficacy and safety of sacituzumab govitecan versus TPC in Asian patients with HR+/HER2- mBC who received at least two, and no more than four systemic chemotherapy regimens. The trial will enroll up to 330 HR+/HER2- mBC patients in China mainland, Taiwan and South Korea. The primary endpoint is progression free survival (PFS) per RECIST v 1.1 by an Independent Review Committee.

“HR+/HER2- breast cancer is the most prevalent subtype of breast cancer and accounts for more than 60% of all breast cancer cases. There is a significant unmet need for new treatment options for women with HR+/HER2− mBC who have failed initial standard-of-care chemotherapies,” said Dr. Yang Shi, Chief Medical Officer for Oncology at Everest Medicines. “The clinical data generated to date suggested promising clinical activity of sacituzumab govitecan in HR+/HER2− mBC patients who have failed at least two chemotherapy regimens. We are very excited to initiate our Phase 3 registration trial as we believe sacituzumab govitecan has tremendous potential to become the new standard of care in patients with pre-treated HR+/HER2− mBC.”

Immunomedics (now part of Gilead Sciences, Inc), which developed sacituzumab govitecan, is currently recruiting patients for the TROPiCS-02 trial, an open-label, randomized, multi-center Phase 3 study to compare the efficacy and safety of sacituzumab govitecan versus the TPC in subjects with metastatic or locally recurrent inoperable HR+/HER2- mBC, after failure of at least two, and no more than four, prior chemotherapy regimens for metastatic disease.

About Sacituzumab Govitecan

Sacituzumab govitecan is a first-in-class antibody-drug conjugate (ADC) directed at TROP-2, a membrane antigen that is over-expressed in many common epithelial cancers. Sacituzumab govitecan was granted accelerated approval by the U.S. FDA in April 2020 for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease. In September 2020 at the ESMO2020 annual conference, Immunomedics (now part of Gilead Sciences, Inc.) presented the confirmatory Phase 3 trial results (ASCENT) demonstrating that sacituzumab govitecan significantly improved progression free survival (PFS) and overall survival (OS) over standard single agent chemotherapy in pre-treated metastatic triple-negative breast cancer (mTNBC) patients with a hazard ratio of 0.41 and 0.48 respectively. Under a licensing agreement with Immunomedics, Everest Medicines has exclusive rights to develop, register, and commercialize sacituzumab govitecan for all cancer indications in Greater China, South Korea, and certain Southeast Asian countries.

In October 2020, sacituzumab govitecan was included in the updated 2020 Guidelines for the Standardized Diagnosis and Treatment of Advanced Breast Cancer in China, compiled by the Breast Cancer Expert Committee of the National Cancer Control Center, the Breast Cancer Professional Committee of the Chinese Anti-Cancer Association, and the Cancer Drug Clinical Research Professional Committee of the Chinese Anti-Cancer Association.

About
HR+/HER2- Breast Cancer

Hormone Receptor Positive, HER2 Negative (HR+/HER2-) breast cancer is the most common form of breast cancer in China, representing over 60% of all breast cancer cases. This subtype of breast cancer grows in connection with estrogen or progesterone and is likely to respond to hormone therapies initially, but almost all HR+/HER2- metastatic breast cancers become refractory over time.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record of high-quality clinical development, regulatory affairs, CMC, business development and operations both in China and with leading global pharmaceutical companies. Everest Medicines has built a portfolio of eight potentially global first-in-class or best-in-class molecules, many of which are in late stage clinical development. The Company’s therapeutic areas of interest include oncology, autoimmune disorders, cardio-renal diseases and infectious diseases. Everest Medicines obtained the development and commercial right in greater China, South Korea and certain Southeast Asian countries of sacituzumab govitecan from Immunomedics in April 2019. For more information, please visit its website at www.everestmedicines.com.

Everest Medicines

Media in US and Europe:
Darcie Robinson
Vice President
Westwicke PR
(203) 919-7905
[email protected]

Media in China:
Edmond Lococo
Managing Director
ICR Asia
+86 (10) 6583-7510
[email protected]

 



Posted on

Agilyx Signs Agreement with A.Eon

Converting Mixed Waste Plastics to Generate Electricity

PR Newswire

TIGARD, Ore. and MELBOURNE, Australia, Dec. 9, 2020 /PRNewswire/ — Agilyx Corporation (AGLX), a pioneer in the advanced recycling of post-use plastics, and A.Eon Holdings Pty Ltd, a market leader in the development of sustainable energy solutions, announced today the initiation of a memorandum of understanding (MoU) to evaluate the construction of a 50 ton per day commercial scale plastics to energy facility utilizing Agilyx technology. This announcement is further progress of Agilyx’s target of 260 tons per day of projects in development by year end 2020.

The planned facility will be located in Melbourne, Victoria, Australia and will convert mixed waste plastic to Agilyx Synthetic Crude Oil (“ASCO”) through Agilyx proprietary advanced plastics recycling technology. The output ASCO would be used by A.Eon to generate electricity for the Victorian State Government’s redeveloped Footscray Hospital project, local industry, as well as to supply peak energy demand. This initial 50 ton per day focus is a starting point, with an option for additional commercial scale facilities to be developed in Australia by A.Eon.

“We are delighted to be working with A.Eon on this truly impactful project,” said Tim Stedman, CEO of Agilyx. “Having an already proven track record in the U.S. converting mixed waste plastics to ASCO, we are looking forward to replicating this for A.Eon in Australia.”

“An exciting start to a great partnership,” said Andrew Lawson, A.Eon’s Managing Director. “A.Eon is pleased to be working with Agilyx. We look forward to seeing this project come to fruition, which will see up to 20,000 tons of waste plastic diverted from landfill and converted into more than 60,000 megawatt-hours of electricity per year.” 

About Agilyx

Agilyx (AGLX), is a pioneer in the advanced recycling of difficult-to-recycle post-use plastic streams. With Agilyx’s chemical recycling technology and intelligent feedstock management system, mixed plastic waste can be converted to new virgin-equivalent plastics, as well as chemical products and fuels – creating the opportunity for true circularity. The company has not only developed these first-to-market products, but has also developed a feedstock management company Cyclyx International, Inc. and is working with many waste service providers, municipalities, petrochemical, and brand and retail companies to develop closed-loop advance recycling solutions for mixed waste plastics. Contact us to have your plastic waste streams recycled at [email protected]. For more information, follow us on social media and visit us at www.agilyx.com.

About A.Eon

A.Eon Holdings Pty Ltd, is a market leader in the development of sustainable energy solutions through the utilization of end-of-use plastics to energy. Established in 2013, the Australian based company has been working to create a comprehensive end-of-use diversion process to meet Australia’s demand for landfill diversion of end-of-use plastics and energy production.


Contacts:

Agilyx

Kate Ringier

VP, Communications & Government Affairs
+41 78 822 7770
[email protected]

A.Eon

Andrew Lawson

Managing Director
+61 22 99 678
[email protected]

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/agilyx/r/agilyx-signs-agreement-with-a-eon,c3251426

 

Cision View original content:http://www.prnewswire.com/news-releases/agilyx-signs-agreement-with-aeon-301189140.html

SOURCE Agilyx

Posted on

Nomination Committee appointed for BioInvent International’s Annual General Meeting 2021

PR Newswire

LUND, Sweden, Dec. 9, 2020 /PRNewswire/ — The members of the Nomination Committee for BioInvent International AB:s (publ) (“BioInvent) Annual General Meeting in 2021 have now been appointed.

The following representatives of BioInvent International AB’s shareholders will be members of the Nomination Committee for the Annual General Meeting 2021:

  • Erik Esveld, appointed by van Herk Investments B.V., Chairman of the Nomination Committee
  • Vincent Ossipow, appointed by Omega Funds, LP
  • Jannis Kitsakis, appointed by the Fourth National Swedish Pension Fund
  • Leonard Kruimer, Chairman of the Board

The Chairman of the Board, Leonard Kruimer, has convened the Nomination Committee to its first meeting.

The Nomination Committee shall prepare proposals for the Annual General Meeting in 2021 regarding Chairman of the General Meeting, Chairman of the Board and other Board members, board remuneration shared among the Chairman and other Board members and possible compensation for committee work.

The Annual General Meeting will be held on April 29, 2021 in Lund, Sweden.

Proposals to the Nomination Committee can be sent to Stefan Ericsson, by mail: BioInvent International AB (publ).), SE-223 70 Lund or telephone: +46 (0)46-46 286 85 50 no later than February 28, 2021.

About BioInvent

BioInvent International AB (OMXS: BINV) is a clinical stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of hematological cancer and solid tumors, respectively. Two preclinical programs in solid tumors are expected to have entered clinical trials by the end of 2020. The company’s validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the company’s own clinical development pipeline or for additional licensing and partnering.

The company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the company’s fully integrated manufacturing unit. More information is available at www.bioinvent.com.

For further information, please contact:

Martin Welschof, CEO                               

+46 (0)46 286 85 50                                  

[email protected]

BioInvent International AB (publ)

Co. Reg. No. Org nr: 556537-7263

Visiting address: Sölvegatan 41

Mailing address: 223 70 LUND

Phone: +46 (0)46 286 85 50

www.bioinvent.com

This information was brought to you by Cision http://news.cision.com

The following files are available for download:

Cision View original content:http://www.prnewswire.com/news-releases/nomination-committee-appointed-for-bioinvent-internationals-annual-general-meeting-2021-301189130.html

SOURCE BioInvent

Posted on

Advantest Announces New Module to Enhance T2000 Platform’s Testing of D-PHY and C-PHY Imaging ICs for Smart Phone Cameras

Versatile Module Offers Industry’s Fastest Capture Speed for D-PHY ICs and First 64-Site Test Solution for Advanced C-PHY Devices

TOKYO, Dec. 09, 2020 (GLOBE NEWSWIRE) — Leading semiconductor test equipment supplier Advantest Corporation (TSE: 6857) has launched a new high-speed CMOS image capture module for its T2000 test platform that enables highly parallel, 64-site testing of both D-PHY and C-PHY devices for the rapidly growing smart phone market. The new T2000 4.8-Gbps CMOS image capture module, known as the 4.8GICAP, is designed to efficiently transfer data from CMOS image sensors (CIS) to the T2000 tester’s high-performance image processor engine (IPE). It is the first mass-produced test solution to achieve a maximum data rate of 3.5 Gsps for advanced C-PHY version 1.2 devices as well as the industry’s fastest capture speed of 4.8 Gbps for D-PHY version 2.1 devices. 

An estimated 75% of CIS devices produced today are used in smart phone cameras. With the latest smart phones incorporating multiple cameras, CIS production is forecasted to grow approximately 41% over the next four years, according to an Advantest study. In addition, the latest CIS devices have high resolution on the order of 100 million pixels. These factors increase demand for test solutions that can handle larger volumes of data than ever before while operating at higher speeds to cost-effectively serve the rapidly expanding smart phone market.

The 4.8GICAP module, combined with Advantest’s 3rd generation IPE, can simultaneously capture images and transfer data to the IPE using a two-bank memory mechanism. This will significantly reduce test time.

The unit is designed for installation on the T2000 ISS tester with a fully compatible test program, prober, light source and device interface. This combination produces CIS measurement tools capable of 64-site parallel testing, which supports latest C-PHY in addition to the MIPI standard D-PHY. The new module delivers industry-leading performance with high-speed transmission lines.

The versatile T2000 test platform enables users to respond quickly to shifting market needs with minimal capital investment while also helping to reduce development times for new designs. Its modular architecture is ideally suited to accommodate new generations of devices.

“By providing a measurement environment that can handle greater data-transfer volumes and faster CIS devices, we are bringing improved cost efficiencies to the smart phone camera market,” said Toshiaki Adachi, vice president of the T2000 Business Unit at Advantest.

The 4.8GICAP module has begun shipping to several key customers.

For more information on the T2000 test platform, visit https://www.advantest.com/products/ic-test-systems/t2000.

About Advantest Corporation

Advantest (TSE: 6857) is the leading manufacturer of automatic test and measurement equipment used in the design and production of semiconductors for applications including 5G communications, the Internet of Things (IoT), autonomous vehicles, artificial intelligence (AI), machine learning, smart medical devices and more. Its leading-edge systems and products are integrated into the most advanced semiconductor production lines in the world. The company also conducts R&D to address emerging testing challenges, produces multi-vision metrology scanning electron microscopes essential to photomask manufacturing, and offers groundbreaking 3D imaging and analysis tools. Founded in Tokyo in 1954, Advantest is a global company with facilities around the world and an international commitment to sustainable practices and social responsibility. More information is available at www.advantest.com.

ADVANTEST CORPORATION 
3061 Zanker Road
San Jose, CA 95134, USA
Tish Kelly-Mick
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3b8b0ced-151f-4cfd-8f48-715b3cf38cbb



Posted on

Chugai’s Enspryng Approved in Taiwan as First Approved Medicine for Neuromyelitis Optica Spectrum Disorder (NMOSD)

Chugai’s Enspryng Approved in Taiwan as First Approved Medicine for Neuromyelitis Optica Spectrum Disorder (NMOSD)

  • Enspryng is the first approved medicine for NMOSD in Taiwan
  • Subcutaneous injection for the treatment of NMOSD in both adults and adolescents
  • Enspryng is the first approved medicine applying Chugai’s proprietary recycling antibody technology
  • Enspryng showed a significantly reduced risk of relapse in people with NMOSD in two global phase III studies

TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced Chugai Pharma Taiwan Ltd., a wholly-owned subsidiary of Chugai, obtained an import drug license from the Taiwan Food and Drug Administration (TFDA) for Chugai’s Enspryng® for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult and adolescent over 12 years old patients who are anti-aquaporin-4 (AQP4) antibody positive.

“We are very pleased that Enspryng, created by Chugai, has been approved for the treatment of NMOSD, a disease with high unmet medical needs that has no approved treatments in Taiwan,” said Chugai’s President and COO, Dr. Osamu Okuda. “Enspryng is the first approved product to apply our proprietary recycling antibody technology and the first NMOSD treatment targeting the IL-6 receptor. Chugai will cooperate with Chugai Pharma Taiwan so that Enspryng may be available to people with NMOSD in Taiwan as soon as possible.”

This approval is based on the results from 2 global phase III clinical studies to show a significantly reduced risk of relapse in people with NMOSD: SAkuraSky Study (NCT02028884) and SAkuraStar Study (NCT02073279). SAkuraSky is a study to evaluate Enspryng in combination with baseline immunosuppressive treatment, and SAkuraStar is a study to evaluate Enspryng as monotherapy.

Enspryng, created by Chugai, is the pH-dependent binding humanized anti-IL-6 receptor antibody, which was the first product developed by applying our proprietary recycling antibody technology. The medicine is believed to prevent relapses by inhibiting the cytokine IL-6 which is a key driver in NMOSD. Enspryng has been approved in Canada, Japan, Switzerland, US, Taiwan, Dominican Republic, Guyana, Indonesia, Australia and Curacao. Enspryng is designated as an orphan drug in Europe. The application was accepted for review by the European Medicines Agency in 2019.

As a leading company in biopharmaceuticals, Chugai will continue to create pharmaceutical products that meet unmet medical needs through the development of innovative technologies and their application, contributing to healthcare and the health of people around the world.

[Reference]

・SAkuraSky study

Results from Phase III SAkuraSky Study for Chugai’s Enspryng in Neuromyelitis Optica Spectrum Disorder Published in The New England Journal of Medicine Online (November 29, 2019)

https://www.chugai-pharm.co.jp/english/news/detail/20191129110000_644.html

・SAkuraStar study

Positive Results from the Second Phase III SAkuraStar Study for Chugai’s Enspryng in Neuromyelitis Optica Spectrum Disorder (NMOSD) Published in The Lancet Neurology (April 24, 2020)

https://www.chugai-pharm.co.jp/english/news/detail/20200424150001_714.html

About neuromyelitis optica spectrum disorder (NMOSD)1

NMOSD is an autoimmune disease of the central nervous system characterized by inflammatory lesions in the optic nerves and spinal cord, and causes a continual and significant decrease in quality of life due to permanent neurological disability. Patients with NMOSD frequently experience a relapsing disease course with repeated attacks leading to accumulating neurological damage and disability. Symptoms may include visual impairment, motor disability, pain leading to decreased quality of life. In some cases, attacks of NMOSD result in death. Aquaporin-4 antibodies (AQP4-IgG), pathogenic antibodies, are detected in around 70-80% of NMOSD people. AQP4-IgG is known to target and damage a specific central nervous cell type called astrocytes, resulting in inflammatory demyelinating lesions of the optic nerve(s), spinal cord and brain 2-5. The inflammatory cytokine IL-6 is now emerging as an important factor in NMOSD pathogenesis 6-10.

Diagnostic criteria introduced in 2006 for NMO were characterized by inflammation of the optic nerve (optic neuritis) and the spinal cord (myelitis). These were revised in 2007 with the definition of NMOSD, proposed for diseases with either optic neuritis or myelitis. In 2015, the definition of NMOSD further revised to include a broader spectrum of diseases. The diagnostic term NMOSD is now accepted 11.

Trademarks used or mentioned in this release are protected by law.

Sources

  1. Neuromyelitis optica spectrum disorder (NMOSD) Online. https://nmosd-online.jp/ Accessed Nov 2020. (Japanese only)
  2. Jarius S, Ruprecht K, Wildemann B et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation 2012;9:14.
  3. Lennon VA, Wingerchuk DM, Kryzer TJ et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106-12.
  4. Marignier R, Bernard-Valnet R, Giraudon P et al. Aquaporin-4 antibody-negative neuromyelitis optica: Distinct assay sensitivity-dependent entity. Neurology 2013;80:2194-200.
  5. Takahashi T, Fujihara K, Nakashima I et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007;130:1235-43.
  6. Chihara N, Aranami T, Sato W et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci USA 2011;108:3701-6.
  7. Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol 2010;40:1830-5.
  8. Lin J, Li X, Xia J. Th17 cells in neuromyelitis optica spectrum disorder: a review. Int J Neurosci2016;126:1051-60.
  9. Takeshita Y, Obermeier B, Cotleur AC, et al. Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro. Neurol Neuroimmunol Neuroinflamm. 2016;4(1):e311.
  10. Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of the blood-brain barrier. Nat Med 2013;19:1584-96.
  11. Wingerchuk DM, Banwell B, Bennett JL et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85:177-89.

 

For Media

Chugai Pharmaceutical Co., Ltd.

Media Relations Group, Corporate Communications Dept.,

Tomoko Shimizu

Tel: +81-3-3273-0881

E-mail: [email protected]

For Taiwanese media

Chugai Pharma Taiwan Ltd.

Susan Chou

Tel: +886-2-2715-2000

E-mail: [email protected]

For Investors

Chugai Pharmaceutical Co., Ltd.

Investor Relations Group, Corporate Communications Dept.,

Toshiya Sasai

Tel: +81-3-3273-0554

E-mail: [email protected]

KEYWORDS: Japan Taiwan Asia Pacific

INDUSTRY KEYWORDS: Biotechnology Health Pharmaceutical Optical Clinical Trials

MEDIA:

Logo
Logo
Posted on

ADVA and Advantech simplify remote uCPE rollout with the launch of a virtual lab

ADVA and Advantech simplify remote uCPE rollout with the launch of a virtual lab

News summary:

  • CSP engineers working remotely to evaluate SD-WAN, security and enterprise edge solutions face logistical challenges
  • ADVA and Advantech’s test-drive portal offers virtual test environment for remote evaluation of SD-WAN and security solutions
  • Initiative removes pain of integration and accelerates uCPE deployment

MUNICH–(BUSINESS WIRE)–
ADVA (FSE: ADV) and Advantech (TWSE: 2395.TW) today announced a joint test-drive portal initiative for remote evaluation of SD-WAN and security solutions on universal CPE (uCPE). Based on the ADVA’s Ensemble suite of network functions virtualization (NFV) technology and Advantech edge appliances, the joint remote lab will streamline the evaluation process for network engineers and architects working remotely by providing them with free access to a wide range of pre-integrated SD-WAN uCPE platforms. The initiative will help communication service providers (CSPs) to overcome the challenges of remote evaluation, such as lab licensing and device shipping to distributed teams.

“We’ve joined forces with ADVA during these challenging times to help network engineers and architects working from home rapidly evaluate different SD-WAN, security and enterprise edge solutions through an open uCPE lab that is fully supported by a team of network experts,” said James Yang, VP, cloud IoT group, Advantech. “This is the first in a series of joint initiatives that will grow our partnership stronger with the objective of delivering hassle-free open uCPE solutions to market that accelerate time to revenue, minimize supply chain risks and support disaggregated SD-WAN strategies toward next-generation converged and cloud-native architectures.”

The new uCPE test-drive portal is built on the ADVA Ensemble open virtualization suite, including carrier-class management and orchestration, and virtual network functions (VNFs) hosting capabilities. Lab users will be provided access to Advantech FWA-1112VC edge appliances hosting the ADVA Ensemble software and will be able to test Fortinet’s Secure SD-WAN solution that enables a security-driven networking approach and the Silver Peak Unity EdgeConnect™ SD-WAN edge platform that provides automated integration with cloud-delivered security services. The Advantech FWA-1112VC platform features Intel Atom® processors that have been cost-optimized for volume deployment and provide flexible connectivity options including 5G, Wi-Fi 6 and 10GbE. Encryption and compression acceleration improvements can be assessed using Intel® QuickAssist with DPDK. Other partner VNFs and Advantech hardware platforms are available for evaluation under request.

“By partnering with Advantech, we’re helping to simplify the virtualization journey for operators and enterprises. This is especially crucial right now with so many CSP and enterprise engineers operating from home. Our joint virtual lab gives those working remotely the ability to see a complete solution and evaluate functionality and performance without having to set it up in their own labs,” said Mike Heffner, VP, product line management, Edge Cloud, ADVA. “Together with Advantech, we’re eliminating the pain of integration and helping our customers realize the benefits of multi-vendor uCPE. This test-drive portal initiative is also key to accelerating the shift towards fully cloud-native architectures.”

Further details on the uCPE test-drive portal are available here: https://adva.li/ucpe-test-drive-portal.

About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.

Published by:

ADVA Optical Networking SE, Munich, Germany

www.adva.com

For press:

Gareth Spence

t +44 1904 699 358

[email protected]

For investors:

Stephan Rettenberger

t +49 89 890 665 854

[email protected]

KEYWORDS: Germany Europe

INDUSTRY KEYWORDS: Software Mobile/Wireless Networks Internet Professional Services Hardware Electronic Design Automation Technology Semiconductor Security Finance Telecommunications

MEDIA:

Posted on

Batelco Sees Growth In Avaya OneCloud Business

PR Newswire

DUBAI, U.A.E, Dec. 9, 2020 /PRNewswire/ —  Batelco, the leading digital solutions provider in the Kingdom of Bahrain, today reported growth in subscriptions to Avaya (NYSE: AVYA) OneCloud UCaaS and Avaya OneCloud CCaaS solutions that it offers as a cloud-based service through Batelco’s Bahrain data centre.

The two companies announced this success story during GITEX Technology Week 2020, marking one year since they signed an agreement to debut the joint services. The dramatic success of the partnership, with seats growing by double digits over the last quarter, reflects Bahrain-based organisations’ demand for the convenience, visibility, and accessibility of enterprise solutions deployed in the cloud.

Batelco offers both public and private cloud-based deployments of Avaya’s cloud solutions to customers and channel partners in Bahrain, by hosting Avaya OneCloud UCaaS and Avaya OneCloud CCaaS solutions at its own data centre.

“Organisations are modernizing their ICT infrastructure by adopting cloud-based services. With Avaya, we saw the opportunity to partner with a company that provides world-class communication solutions on the cloud and is fully committed to offering these platforms as a subscription-based service,” said Abderrahmane Mounir, General Manager, Enterprise, Batelco. “Our joint offering with Avaya suits organisations of all sizes that want to deploy cloud-based industry-leading solutions without the complexities and overheads of on-premise deployment.”

Fadi Hani, Vice President – Middle East, Africa & Turkey, Avaya, said: “Avaya is proud to partner with leading telecoms companies and our success with Batelco shows the benefits of working with the leading solution providers in each market. Together, Avaya and Batelco are helping to facilitate cloud migration for businesses in Bahrain. Our goal is to enable organisations, of any size, to easily and affordably embrace cloud-based UC and CC solutions.”

Avaya’s presence at GITEX Technology Week is in partnership with Extreme Networks, Verint Systems Inc., Semafone, Koopid, Imperium, Calabrio, IR and Nectar. Visit Avaya at Stand Z1-B10, Zabeel Hall, at Dubai World Trade Centre between December 6 and 10, 2020, or join online using the GITEX Unlimited platform.

 

 

 

Cision View original content:http://www.prnewswire.com/news-releases/batelco-sees-growth-in-avaya-onecloud-business-301189118.html

SOURCE Avaya

Posted on

Metapack Announces TDC 2021 to Take Place Virtually in February

Metapack Announces TDC 2021 to Take Place Virtually in February

Leading retailers, brands and carriers to be brought together in a global virtual event

LONDON & EL SEGUNDO, Calif.–(BUSINESS WIRE)–Metapack, the global leader in eCommerce delivery technology, today announced that The Delivery Conference (TDC), the world’s foremost eCommerce delivery event is going virtual. Taking place from February 2-3 2021, TDC will for the first time, be broadcast as a completely virtual event, allowing attendees to tune in to this unmissable eCommerce and delivery conference, no matter where they are in the world.

Global retailers, 400+ carriers and 4,900+ delivery services

Metapack, placed at the heart of the eCommerce ecosystem through its work with leading retailers and with its library of 400+ carriers and 4,900+ delivery services is bringing together thought-leaders, innovators and influences from around the world to one place.

Now in its 12th year and with the effects of the global pandemic having far reaching consequences on the retail landscapes forever, TDC is the must-attend event for anybody with an interest in the future of eCommerce. Attendees will hear from the greatest minds in the industry and learn about the newest innovations in delivery and shipping solutions as we head into the post-pandemic world of tomorrow.

Key takeaways from TDC 2021

  • Discover the key developments and trends impacting eCommerce delivery and last mile right now
  • Hear first-hand how the world’s biggest and most successful brands are responding to the new retail landscape
  • Be part of an unprecedented live global event attended by 1000+ senior industry leaders

What Attendees will Discover:

  • The next big challenges for pandemic era retail and beyond
  • Retaining new customers in an unpredictable consumer landscape
  • What eCommerce can expect from the all-delivery era

“2020 has been a year unlike any we’ve seen before,” commented Bruce Fair, Chief Revenue Officer at Metapack. “The pandemic has completely changed the face of eCommerce and the relationship that consumers have with retail. TDC has long been a staple in the eCommerce events calendar and we’re thrilled that we can now bring this to an even bigger audience virtually. The 2021 event will not disappoint with brilliant speakers and presentations, stimulating panels and insights into emerging trends as together we embark on this new era of retail.”

Register for TDC 2021

To find out more about TDC 2021 and to register, please visit: https://www.thedeliveryconference.com/

About Metapack

Founded in 1999, Metapack helps eCommerce and delivery professionals meet consumers’ growing expectations of delivery, while maintaining and optimizing operational efficiency. Metapack’s SaaS solution offers a wide range of personalized delivery services, from global order tracking to simplified return procedures, through a catalogue of 400+ carriers and 4,900+ services available that span every country in the world. Thanks to Metapack, more than 550 million packages are sent annually by any of the world’s leading eCommerce retailers. Metapack is a wholly-owned subsidiary of Stamps.com (Nasdaq: STMP).

Munveer Garcha

PR and Communications Manager

+44 7925 146339

[email protected]

KEYWORDS: California Europe United States United Kingdom North America

INDUSTRY KEYWORDS: Online Retail Retail Technology Logistics/Supply Chain Management Transport Software Other Transport

MEDIA:

Logo
Logo
Posted on

Mycronic receives order for SLX system

PR Newswire

STOCKHOLM, Dec. 9, 2020 /PRNewswire/ — Mycronic AB (publ) has received an order for an SLX mask writer from an existing customer in Asia. The order has a value of between USD 4-5 million. Delivery of the SLX system is scheduled for the third quarter of 2021.

The SLX laser mask writer was launched at the end of October 2019 to meet rising demand for photomasks for the semiconductor industry, which is driven by long-term trends, and to meet the future need for replacement and modernization. Photomasks made by laser mask writers are very important in the manufacture of semiconductors and account for 70-75 percent of all photomasks produced. SLX is a new and modern mask writer based on the same technology as mask writers for displays.

“It is gratifying that in growing and strategically important market we now have this opportunity to delivery SLX to one of our existing customers. With the introduction of SLX, Mycronic has broadened and strengthened its offering in the mask writer segment, which is reflected in the high level of interest shown by the market,” says Charlott Samuelsson, Sr VP Pattern Generators at Mycronic.

Mycronic provides mask writers for manufacturing photomasks in several fields of application. These comprise display manufacturing (TVs, smartphones and tablets), production of semiconductors and applications in the multi-purpose market, a broad segment that comprises many different areas of application.

For additional information, please contact:

Charlott Samuelsson

Sr VP Pattern Generators
Tel: +46 709 844 282, e-mail: [email protected]

Tobias Bülow
Director Investor Relations
Tel: +46 734 018 216, e-mail: [email protected] 

The information in this press release was published on December 9, 2020, at CET 08:00 a.m.

About Mycronic

Mycronic AB is a Swedish high-tech company engaged in the development, manufacture and marketing of production equipment with high precision and flexibility requirements for the electronics industry. Mycronic’s headquarters are located in Täby, north of Stockholm and the Group has subsidiaries in France, Japan, China, the Netherlands, Singapore, the United Kingdom, South Korea, Germany and the USA. Mycronic is listed on Nasdaq Stockholm. www.mycronic.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/mycronic-ab/r/mycronic-receives-order-for-slx-system,c3251253

The following files are available for download:

 

Cision View original content:http://www.prnewswire.com/news-releases/mycronic-receives-order-for-slx-system-301189100.html

SOURCE Mycronic AB

Posted on

ASE Technology Holding Co., Ltd. Announces Monthly Net Revenues*

PR Newswire

TAIPEI, Taiwan, R.O.C., Dec, 9, 2020 /PRNewswire/ — ASE Technology Holding Co., Ltd. (NYSE: ASX, TAIEX: 3711, “ASEH” or the “Company”), announces its unaudited consolidated net revenues for November 2020.

CONSOLIDATED NET REVENUES (UNAUDITED)

Nov

Oct

Nov

Sequential

YoY

(NT$ Million)

2020

2020

2019

Change

Change

Net Revenues

50,665

47,915

38,456

+5.7%

+31.7%

Nov

Oct

Nov

Sequential

YoY

(US$ Million)

2020

2020

2019

Change

Change

Net Revenues

1,759

1,652

1,264

+6.5%

+39.2%

Net revenues for ATM assembly, testing and material business are as follows:

ATM NET REVENUES (UNAUDITED)

Nov

Oct

Nov

Sequential

YoY

(NT$ Million)

2020

2020

2019

Change

Change

Net Revenues

24,286

23,075

22,838

+5.2%

+6.3%

Nov

Oct

Nov

Sequential

YoY

(US$ Million)

2020

2020

2019

Change

Change

Net Revenues

843

796

751

+6.0%

+12.3%

*This press release is intended to comply with Taiwan regulatory requirements.

Safe Harbor Notice:

This press release contains “forward-looking statements” within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Although these forward-looking statements, which may include statements regarding our future results of operations, financial condition or business prospects, are based on our own information and information from other sources we believe to be reliable, you should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan” and similar expressions, as they relate to us, are intended to identify these forward-looking statements in this press release. These forward-looking statements are necessarily estimates reflecting the best judgment of our senior management and our actual results of operations, financial condition or business prospects may differ materially from those expressed or implied by the forward-looking statements for reasons including, among others, risks associated with cyclicality and market conditions in the semiconductor or electronic industry; changes in our regulatory environment, including our ability to comply with new or stricter environmental regulations and to resolve environmental liabilities; demand for the outsourced semiconductor packaging, testing and electronic manufacturing services we offer and for such outsourced services generally; the highly competitive semiconductor or manufacturing industry we are involved in; our ability to introduce new technologies in order to remain competitive; international business activities; our business strategy; our future expansion plans and capital expenditures; the strained relationship between the Republic of China and the People’s Republic of China; general economic and political conditions; the recent shift in United States trade policies; possible disruptions in commercial activities caused by natural or human-induced disasters; fluctuations in foreign currency exchange rates; and other factors. For a discussion of these risks and other factors, please see the documents we file from time to time with the Securities and Exchange Commission, including the 2019 Annual Report on Form 20-F filed on March 31, 2020.

Investor Relations Contact:

Cision View original content:http://www.prnewswire.com/news-releases/ase-technology-holding-co-ltd-announces-monthly-net-revenues-301189000.html

SOURCE ASE Technology Holding Co., Ltd.